160 related articles for article (PubMed ID: 28534527)
1. Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Luo S; Chen G; Truica C; Baird CC; Leitzel K; Lazarus P
Pharmacogenomics J; 2018 Apr; 18(2):295-300. PubMed ID: 28534527
[TBL] [Abstract][Full Text] [Related]
2. Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane.
Luo S; Chen G; Truica CI; Baird CC; Xia Z; Lazarus P
Drug Metab Dispos; 2018 Dec; 46(12):1867-1878. PubMed ID: 30257855
[TBL] [Abstract][Full Text] [Related]
3. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
[TBL] [Abstract][Full Text] [Related]
4. Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane.
Teslenko I; Trudeau J; Luo S; Watson CJW; Chen G; Truica CI; Lazarus P
J Pharmacol Exp Ther; 2022 Sep; 382(3):327-334. PubMed ID: 35793834
[TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.
Lazarus P; Zheng Y; Runkle EA; Muscat JE; Wiener D
Pharmacogenet Genomics; 2005 Nov; 15(11):769-78. PubMed ID: 16220109
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.
Sun D; Chen G; Dellinger RW; Sharma AK; Lazarus P
Pharmacogenet Genomics; 2010 Oct; 20(10):575-85. PubMed ID: 20697310
[TBL] [Abstract][Full Text] [Related]
7. Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Chanawong A; Mackenzie PI; McKinnon RA; Hu DG; Meech R
J Pharmacol Exp Ther; 2017 Jun; 361(3):482-491. PubMed ID: 28404691
[TBL] [Abstract][Full Text] [Related]
8. Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.
Chen G; Luo S; Kozlovich S; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1175-1184. PubMed ID: 27197298
[TBL] [Abstract][Full Text] [Related]
9.
Teslenko I; Watson CJW; Chen G; Lazarus P
Mol Pharmacol; 2022 Aug; 102(5):216-22. PubMed ID: 35953090
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Cytosolic Glutathione
Teslenko I; Watson CJW; Xia Z; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1047-1055. PubMed ID: 34593616
[TBL] [Abstract][Full Text] [Related]
11. Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.
Ho V; Pasquet R; Luo S; Chen G; Goss P; Tu D; Lazarus P; Richardson H;
Breast Cancer Res Treat; 2020 Oct; 183(3):705-716. PubMed ID: 32715442
[TBL] [Abstract][Full Text] [Related]
12. Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers.
Chen SM; Atchley DH; Murphy MA; Gurley BJ; Kamdem LK
J Clin Pharmacol; 2016 Jul; 56(7):875-84. PubMed ID: 26608382
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Johansson H; Aristarco V; Gandini S; Gjerde J; Macis D; Guerrieri-Gonzaga A; Serrano D; Lazzeroni M; Rajasekaran A; Williard CV; Mellgren G; DeCensi A; Bonanni B
Pharmacogenomics J; 2020 Feb; 20(1):19-26. PubMed ID: 30967597
[TBL] [Abstract][Full Text] [Related]
14. In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17
Peterson A; Xia Z; Chen G; Lazarus P
Pharmacol Res Perspect; 2017 Jun; 5(3):e00314. PubMed ID: 28603633
[TBL] [Abstract][Full Text] [Related]
15. Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Wong NS; Seah EZh; Wang LZ; Yeo WL; Yap HL; Chuah B; Lim YW; Ang PC; Tai BC; Lim R; Goh BC; Lee SC
Pharmacogenet Genomics; 2011 Nov; 21(11):760-8. PubMed ID: 21849928
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions
Kahma H; Filppula AM; Neuvonen M; Tarkiainen EK; Tornio A; Holmberg MT; Itkonen MK; Finel M; Neuvonen PJ; Niemi M; Backman JT
Drug Metab Dispos; 2018 Feb; 46(2):141-150. PubMed ID: 29138287
[TBL] [Abstract][Full Text] [Related]
17. Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.
Platt A; Xia Z; Liu Y; Chen G; Lazarus P
Pharmacogenet Genomics; 2016 Aug; 26(8):370-80. PubMed ID: 27111237
[TBL] [Abstract][Full Text] [Related]
18. Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
Chen G; Giambrone NE; Lazarus P
Pharmacogenet Genomics; 2012 Mar; 22(3):183-90. PubMed ID: 22228205
[TBL] [Abstract][Full Text] [Related]
19. Effect of UGT2B17 deletion polymorphism on prognosis in pediatric cancer.
Ishimaru S; Yuza Y; Kaneko T; Urashima M
Pediatr Int; 2017 Apr; 59(4):427-431. PubMed ID: 27805301
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.
Bhatt DK; Basit A; Zhang H; Gaedigk A; Lee SB; Claw KG; Mehrotra A; Chaudhry AS; Pearce RE; Gaedigk R; Broeckel U; Thornton TA; Nickerson DA; Schuetz EG; Amory JK; Leeder JS; Prasad B
Drug Metab Dispos; 2018 Jun; 46(6):888-896. PubMed ID: 29602798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
